Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

KYTH 48.33 -2.11 (-4.18%)
price chart
KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) Major Catalyst on May13th
KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) is a clinical stage biopharmaceutical company focused on the aesthetic medicine market.
Kythera Biopharmaceuticals Inc. (KYTH) is Trading Lower on Unusual Volume ...  Equities.com
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
FDA Panel Backs Drug that Reduces Double Chin  Newsmax
Is Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) Stock a Sell after Keith ...
At an average stock price per share of $50.5, Keith Leonard, the Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 49.16 -0.29 -0.59% 's President & CEO unloaded 2,709 shares of Kythera Biopharmaceuticals Inc worth roughly $136,869 US Dollars. This is ...
Insider Selling: Kythera Biopharmaceuticals CEO Sells $136858.68 in Stock ...  The Legacy
Reasons for Keith Leonard's Shares Sale of Kythera Biopharmaceuticals Inc ...
13,548 shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) were unloaded by Keith Leonard, the corporation's President & CEO.
Kythera Biopharmaceuticals CEO Keith R. Leonard Sells 13548 Shares (KYTH)  WKRB News
KYTHERA Biopharmaceuticals Announces FDA Advisory Committee ...
WESTLAKE VILLAGE, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S.
FDA Panel Backs Kythera Double-Chin Treatment  Wall Street Journal
Brokerage Firm Focus: Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)
On a consensus basis, Street analysts are expecting Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) to report earnings per share of $-1.11 for the quarter ending 2015-03-31.
KYTHERA Biopharmaceuticals Announces 2014 Operating Results
WESTLAKE VILLAGE, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its quarter and year ended December 31, 2014, and provided an update on recent accomplishments.
Kythera Biopharmaceuticals (KYTH) Releases Earnings Results, Meets Estimates  The Legacy
Update: Short Interest of Kythera Biopharmaceuticals, Inc. Drops by -1%
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) encountered a drop of 1% or -46,666 shares in the short positions. The number dropped from 4,621,913 on March 13,2015 to 4,575,247 on March 31,2015 .
Wall Street Analysts Have $62.333 Price Target on Kythera Biopharmaceuticals ...  The Markets Daily
Today's Pre-Market Info: Kythera Biopharmaceuticals, Inc. (KYTH), Cytec ...  WallStreet Scope
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
KYTHERA Biopharmaceuticals, Inc. KYTH, +0.20% today announced that on March 27, 2015, the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase an aggregate of 40,000 shares of the ...
Kythera Biopharmaceuticals (KYTH) Enters Overbought Territory
Yet KYTH's high RSI value isn't the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Kythera Biopharmaceuticals' stock as of late. This is especially true when investors dive into some ...
Commit To Buy Kythera Biopharmaceuticals At $30, Earn 11.9% Annualized ...  Nasdaq